Choose a date range

From To

Choose one or more categories


Show only original CenterWatch stories


Juno Therapeutics, Editas Medicine collaborate on cancer therapies

Friday, May 29, 2015 02:39 PM

Juno Therapeutics, a Seattle-based biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, and Editas Medicine, a Camrbidge, Mass.-based genome editing company, are collaborating on creating chimeric antigen receptor (CAR T) and high-affinity T cell receptor (TCR) therapies to treat cancer. The companies will pursue three research programs together utilizing Editas’ genome editing technologies, including CRISPR/Cas9, with Juno’s CAR and TCR technologies.

More... »

Quest Diagnostics

Cenduit to hire globally

Friday, May 29, 2015 02:38 PM

Cenduit, a joint venture between Quintiles and Thermo Fisher Scientific, has hired 43 new professionals so far in 2015 and is actively looking to fill a number of new positions in the U.S. and abroad.

More... »

Pfizer launches $3M grants program to further breast cancer research

Friday, May 29, 2015 02:37 PM

Pfizer has launched a competitive, peer-reviewed grants program to support clinical research projects investigating Ibrance (palbociclib) in advanced breast cancer.

More... »

Quintiles opens Greater China regional headquarters in Shanghai

Friday, May 29, 2015 02:36 PM

Quintiles has opened the Quintiles Greater China Regional Headquarters 17 years after Quintiles first opened an office in Shanghai with 20 employees across Greater China. Quintiles’ 43,000 square feet headquarters in Shanghai’s Feng Lin Science Park now has almost 300 employees and is designed to host 450.

More... »

Janssen, Bayer initiate anticoagulant rivaroxaban trials

Friday, May 29, 2015 01:54 PM

Janssen Pharmaceuticals and its development partner, Bayer HealthCare, have initiated CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types.

More... »

Amgen releases phase III AMG 416 data for secondary hyperparathyroidism in CKD

Friday, May 29, 2015 01:46 PM

Amgen has released pooled data from two pivotal phase III, global, randomized, placebo-controlled trials evaluating AMG 416, a novel calcimimetic, for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) receiving hemodialysis. Both studies met the primary endpoint, demonstrating that a greater proportion of patients in the AMG 416 groups achieved a greater than 30% reduction in parathyroid hormone (PTH) during the efficacy assessment phase compared with placebo.

More... »

Gilead opens innovative new laboratory, announces additional $100M investment

Thursday, May 28, 2015 03:13 PM

Gilead Alberta, a wholly-owned subsidiary of Gilead Sciences, has opened the first of two new laboratory buildings at its Edmonton, Canada campus, and announced an additional $100 million investment to further expand and upgrade the site as the biopharmaceutical company broadens its pipeline of treatments in areas of unmet medical need.

More... »

Allergen Research changes name to Aimmune Therapeutics

Thursday, May 28, 2015 03:12 PM

Allergen Research, a Brisbane, Calif.-based privately held biopharmaceutical company developing desensitization treatments for food allergies, has changed its name to Aimmune Therapeutics.

More... »

Clinerion, ACRES partner on patient recruitment, risk-based quality management

Thursday, May 28, 2015 03:10 PM

Clinerion, an eClinical technology services provider located in Basel, Switzerland, and the Alliance for Clinical Research Excellence and Safety (ACRES), a Cambridge, Mass.-based nonprofit, have partnered for accelerating patient recruitment and promoting risk-based quality management.

More... »

DaVita Clinical Research expands nephrology clinical trial capabilities in Europe

Thursday, May 28, 2015 03:09 PM

DaVita Clinical Research (DCR), a specialty CRO based in Minneapolis has expanded its clinical trials capabilities in Europe. DCR now will be able to facilitate the conduct of late phase clinical trials in several medical centers outside of the U.S. Physician leaders from Germany, Poland and Portugal, with a combined 20 years of research experience, will collaborate with DCR to provide data and knowledge-based insights to its clients.

More... »


May 26

inVentiv Health aims to help sponsors prepare for new E.U. regulations on observational studies

ACRP partners with CRO Analytics to measure investigative sites' views of clinical trial quality

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs